The Network has been instrumental in building an infrastructure prompting several of the above-mentioned EU-funded projects:

  • ADDUCE (Attention-Deficit Hyperactivity Disorder Drugs Use Chronic Effects, www.adhd-adduce.org
  • TACTICS (The “Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes”, www.tactics-project.eu)
  • AGGRESSOTYPE (“Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders”, www.aggressotype.eu)
  • MATRICS (“Multidisciplinary Approaches to Translational Research In Conduct Syndromes”, www.matrics-project.eu)

Other projects have been submitted to the Ho2020 program in October 2014:

  • APPLE, Antipsychotics in the paediatric population: limiting exposure (CIMH, UNIDUN, RUNMC, UNICA, CIBERSAN, and others). Failed.
  • OPTI-MED, Establishing optimal ADHD medication strategies across Europe  (UMGC, UNIDUN, UNIDRE, UNICA and others). Failed.
  • TAPS Treatment of ADHD in pre-schoolers (UNIDUN,RUNMC, UNICA and others). Failed.
  • NIOTAS Neuroimmune Interactions in ObsessiveCompulsive, Tourette’s, AttentionDeficit/ Hyperactivity and Autism Spectrum Disorders (UNIDUN, UMCG, UNICA, UCBM and others). Failed.
  • NIOTAS Neuroimmune Interactions in ObsessiveCompulsive, Tourette's, AttentionDeficit/Hyperactivity and Autism Spectrum Disorders (UNIDUN, UMCG, UNICA, UCBM and others). Failed.
  • COBRA, COmputational approaches for Biomarker Identification in Attention Deficit HypeRActivity Disorder (ADHD) (UNIDUN, RUNMC, CIMH, UCBM, UNICA, and others). Failed after passing to second stage.

Unmet needs in pediatric psychopharmacology: present scenario and future perspectives. AM Persico, C Arango, JK Buitelaar, CU Correll, JC Glennon, PJ Hoekstra, C Moreno, B Vitiello, J Vorstman, A Zuddas, and the European Child and Adolescent Clinical Psychopharmacology Network. European Neuropsychopharmacology (2015), in press (http://dx.doi.org/10.1016/j.euroneuro.2015.06.009). Highlights of the article:

  • The off-label prescription to children and adolescents of medications with regulatory approval only in adults
  • The lack of effective drugs for many childhood disorders
  • In search for evidence-based approaches to prevent mental disorders with adolescent-onset
  • The need for better preclinical data to foster novel drug therapies
  • Paediatric clinical trials: methodological issues, problems and potential solutions
  • The regulatory context of paediatric psychopharmacology in Europe: strengths and limitations
  • The potential limit set by categorical psychiatric nosology on paediatric drug development
  • Limited public acceptance of treating children with medications
  • European collaborative efforts and future directions